Turning Healthcare Challenges into Big Data Opportunities: A Use-Case Review Across the Pharmaceutical Development Lifecycle.
In order to draw meaning from the exponentially increasing quantity of healthcare data, it must be dealt with from a big data perspective, using technologies capable of processing massive amounts of data efficiently and securely. The pharmaceutical industry faces the big data challenge through all p...
| Publicado en: | Bulletin of the Association for Information Science & Technology Vol. 39; no. 5; pp. 34 - 41 |
|---|---|
| Autor principal: | |
| Formato: | tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Jun/Jul2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=88846056&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 88846056 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23739223 H7HM jtl: Bulletin of the Association for Information Science & Technology issn: 23739223 maglogo: N pubinfo: dt: Jun/Jul2013 vid: 39 iid: 5 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 88846056 104187595 104187595 10.1002/bult.2013.1720390508 88846056 ppf: 34 ppct: 7 formats: fmt: @attributes: type: P tig: atl: Turning Healthcare Challenges into Big Data Opportunities: A Use-Case Review Across the Pharmaceutical Development Lifecycle. aug: au: Schultz, Timothy affil: College of Information Science & Technology (The iSchool), Drexel University sug: subj: Data Management Drug Design Trends Computers and Computerization Trends Cloud Computing Genomics Bladder Neoplasms Familial and Genetic Polymorphism, Genetic Monitoring, Physiologic Accelerometers Collaboration Alzheimer's Disease Autism Spectrum Disorder Patient Protection and Affordable Care Act Pharmacovigilance ab: In order to draw meaning from the exponentially increasing quantity of healthcare data, it must be dealt with from a big data perspective, using technologies capable of processing massive amounts of data efficiently and securely. The pharmaceutical industry faces the big data challenge through all phases of the drug development lifecycle. Genomics, clinical monitoring and pharmacovigilance illustrate the value of a big data approach. Whether focusing on genetic and environmental disease risks, pattern detection through real time biosensors for patients or post-market monitoring of drug effectiveness, each area involves the collection and analysis of numerous variables and requires extreme computing power to reveal the details of interplay between the variables. To make big data work for pharmaceutical information, attention must be paid to data collection on a vast scale, from multiple sites and over long time periods. Big data support must be incorporated into interoperable electronic medical records and presented intuitively through visual analytics. pubtype: Periodical doctype: tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|